Our results indicated that salirasib significantly decreases the mRNA levels of H‐Ras in SSc fibroblasts, which is consistent with previous study showing that salirasib can decrease Ras expression and activity in a dose‐ and time‐dependent manner [44]. Here, HRAS is linked to systemic sclerosis.